WO2019156565A1 - Improved antagonistic anti-human cd40 monoclonal antibodies - Google Patents

Improved antagonistic anti-human cd40 monoclonal antibodies Download PDF

Info

Publication number
WO2019156565A1
WO2019156565A1 PCT/NL2019/050086 NL2019050086W WO2019156565A1 WO 2019156565 A1 WO2019156565 A1 WO 2019156565A1 NL 2019050086 W NL2019050086 W NL 2019050086W WO 2019156565 A1 WO2019156565 A1 WO 2019156565A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cell
sequence
antigen binding
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2019/050086
Other languages
English (en)
French (fr)
Inventor
Anton Egbert Peter Adang
Mark De Boer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fast Forward Pharmaceuticals BV
Original Assignee
Fast Forward Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP19714877.8A priority Critical patent/EP3752532A1/en
Priority to AU2019217207A priority patent/AU2019217207B2/en
Priority to JP2020565253A priority patent/JP2021513367A/ja
Priority to CN201980025343.4A priority patent/CN112119092A/zh
Priority to CA3090322A priority patent/CA3090322A1/en
Priority to KR1020207025757A priority patent/KR20200141986A/ko
Application filed by Fast Forward Pharmaceuticals BV filed Critical Fast Forward Pharmaceuticals BV
Publication of WO2019156565A1 publication Critical patent/WO2019156565A1/en
Priority to US16/987,903 priority patent/US11396552B2/en
Anticipated expiration legal-status Critical
Priority to US17/742,702 priority patent/US20230059094A1/en
Priority to JP2024002623A priority patent/JP2024024118A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • the CD40 molecule is a type I membrane glycoprotein of 50kDa. This protein is mainly expressed on the surface of antigen presenting cells including, B-cells, monocytes/macrophages and dendritic cell (DCs) and can also be found on a large variety of other cell types including, endothelial cells, smooth muscle cells, fibroblasts, epithelial cell and keratinocyt.es.
  • the ligand for the CD40 receptor is CD40L, also called CD 154.
  • This 32 kDa protein is a type II integral membrane glycoprotein and is transiently expressed on activated CD4 + T cells and a small population of activated CD8 + T cells.
  • CD40L has been found on a number of other immune cells and other cell types. CD40 and its ligand (CD40L) belong to the tumor necrosis factor (TNF) superfamily.
  • TNF tumor necrosis factor
  • VL-4 DI VMTQ S PLS LP VT PGQ PAS ISCRSSQS LASS Q GNTYLH WYLQ KPGQ S P RLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTH
  • PG102_var2 PG102_var3, PG102_var5, PG102_var6 and PG102_varl6.
  • PG102_varl and PG102_varl0 show reduced biological activity at the level of 1 and 10 ng/ml and are possibly less effective than PG102_wt (Table 4). For PG102_var 10, this corresponds with the CD40 binding data, showing reduced binding affinity for the antibody variants carrying the VL3 (Table 2).
  • a set of aggregation and PTM mitigating sequences were designed and ranked based on their potential to reduce the risk of aggregation or PTMs without negatively affecting binding affinity. Sequence and structural comparisons were made as necessary.
  • Neutral substitutions are generally solvent exposed positions in the framework and more than 5A from any side chain atoms of any CDR residues. Residues within this region are classed as Contributing to the affinity. Contributing positions may be substituted, and in many cases this is done in order to efficiently humanize, deimmunize or otherwise engineer an antibody. The risk category of all positions is continually re-evaluated in the context of other substitutions.
  • the engineered light chain focusses on the CDR LI PTMs and has a single engineered chain with additional substitutions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/NL2019/050086 2018-02-12 2019-02-11 Improved antagonistic anti-human cd40 monoclonal antibodies Ceased WO2019156565A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2019217207A AU2019217207B2 (en) 2018-02-12 2019-02-11 Improved antagonistic anti-human CD40 monoclonal antibodies
JP2020565253A JP2021513367A (ja) 2018-02-12 2019-02-11 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
CN201980025343.4A CN112119092A (zh) 2018-02-12 2019-02-11 改进的拮抗性抗人cd40单克隆抗体
CA3090322A CA3090322A1 (en) 2018-02-12 2019-02-11 Improved antagonistic anti-human cd40 monoclonal antibodies
KR1020207025757A KR20200141986A (ko) 2018-02-12 2019-02-11 개선된 길항성 항-인간 cd40 단클론 항체
EP19714877.8A EP3752532A1 (en) 2018-02-12 2019-02-11 Improved antagonistic anti-human cd40 monoclonal antibodies
US16/987,903 US11396552B2 (en) 2018-02-12 2020-08-07 Antagonistic anti-human CD40 monoclonal antibodies
US17/742,702 US20230059094A1 (en) 2018-02-12 2022-05-12 Improved antagonistic anti-human cd40 monoclonal antibodies
JP2024002623A JP2024024118A (ja) 2018-02-12 2024-01-11 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18156288 2018-02-12
EP18156288.5 2018-02-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/987,903 Continuation US11396552B2 (en) 2018-02-12 2020-08-07 Antagonistic anti-human CD40 monoclonal antibodies

Publications (1)

Publication Number Publication Date
WO2019156565A1 true WO2019156565A1 (en) 2019-08-15

Family

ID=61192786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2019/050086 Ceased WO2019156565A1 (en) 2018-02-12 2019-02-11 Improved antagonistic anti-human cd40 monoclonal antibodies

Country Status (8)

Country Link
US (2) US11396552B2 (https=)
EP (1) EP3752532A1 (https=)
JP (2) JP2021513367A (https=)
KR (1) KR20200141986A (https=)
CN (1) CN112119092A (https=)
AU (1) AU2019217207B2 (https=)
CA (1) CA3090322A1 (https=)
WO (1) WO2019156565A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021246413A1 (https=) * 2020-06-02 2021-12-09
US11396552B2 (en) 2018-02-12 2022-07-26 Diabetes-Free Inc. Antagonistic anti-human CD40 monoclonal antibodies
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
RU2836869C1 (ru) * 2020-06-02 2025-03-24 Тейдзин Фарма Лимитед Гуманизированное антитело против рецептора igf-1
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
US12465029B2 (en) 2014-12-10 2025-11-11 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115403670B (zh) * 2021-05-26 2026-03-10 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
WO2025122817A1 (en) * 2023-12-06 2025-06-12 The General Hospital Corporation Antagonistic cd40 antibodies
KR20250116195A (ko) * 2024-01-24 2025-08-01 서울대학교산학협력단 Cd40에 특이적으로 결합하는 항체 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044294A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Method of therapy for cancers expressing the cd40 antigen
WO2007129895A2 (en) 2006-05-09 2007-11-15 Pangenetics B.V. Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2011123489A2 (en) * 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies
WO2016196314A1 (en) * 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1178786B (it) 1984-12-21 1987-09-16 Assorenti Analoghi retro-inverso parzialmente modificati della neurotensina
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU649217B2 (en) 1988-11-18 1994-05-19 Regents Of The University Of California, The Method for site-specifically incorporating unnatural amino acids into proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
HUT71860A (en) 1992-08-27 1996-02-28 Deakin Res Ltd Retro-, inverso-, and retro-inverso synthetic peptide analogues
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6339069B1 (en) 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6103489A (en) 1997-03-21 2000-08-15 University Of Hawaii Cell-free protein synthesis system with protein translocation and processing
CA2303268A1 (en) 1997-06-13 1998-12-17 Scott Walsh Therapeutic nanospheres
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
FR2840307B1 (fr) 2002-05-30 2006-07-07 Centre Nat Rech Scient Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
WO2005006949A2 (en) 2003-07-07 2005-01-27 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7659252B2 (en) 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
US20070237826A1 (en) 2006-04-05 2007-10-11 Rao Kollipara K Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
AR060487A1 (es) * 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
EP2067785A1 (en) 2007-12-03 2009-06-10 Fresenius Medical Care Deutschland GmbH Human CD154-binding synthetic peptide and uses thereof
US8734786B2 (en) 2009-09-16 2014-05-27 Northwestern University Use of ECDI-fixed cell tolerance as a method for preventing allograft rejection
WO2011069037A2 (en) 2009-12-03 2011-06-09 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
ES2957957T3 (es) 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
CA2832281C (en) 2011-04-04 2019-11-05 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
WO2012145632A1 (en) 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
KR101329411B1 (ko) 2012-05-31 2013-11-14 주식회사 엘지생활건강 피부투과성 펩타이드
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
US20180172683A1 (en) 2015-06-22 2018-06-21 University Of Southern California Methods for analyzing the interaction between a target protein and a ligand
KR101810778B1 (ko) 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
JP2021513367A (ja) * 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044294A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Method of therapy for cancers expressing the cd40 antigen
WO2007129895A2 (en) 2006-05-09 2007-11-15 Pangenetics B.V. Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2011123489A2 (en) * 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies
WO2016196314A1 (en) * 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP3752532A1
WILLIAM BENSINGER ET AL: "A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma", BRITISH JOURNAL OF HAEMATOLOGY, vol. 159, no. 1, 1 October 2012 (2012-10-01), GB, pages 58 - 66, XP055598577, ISSN: 0007-1048, DOI: 10.1111/j.1365-2141.2012.09251.x *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12465029B2 (en) 2014-12-10 2025-11-11 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US11396552B2 (en) 2018-02-12 2022-07-26 Diabetes-Free Inc. Antagonistic anti-human CD40 monoclonal antibodies
JPWO2021246413A1 (https=) * 2020-06-02 2021-12-09
WO2021246413A1 (ja) * 2020-06-02 2021-12-09 帝人ファーマ株式会社 抗ｉｇｆ－１受容体ヒト化抗体
CN115605594A (zh) * 2020-06-02 2023-01-13 帝人制药株式会社（Jp） 抗igf-1受体人源化抗体
RU2836869C1 (ru) * 2020-06-02 2025-03-24 Тейдзин Фарма Лимитед Гуманизированное антитело против рецептора igf-1
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
US12274747B2 (en) 2021-01-28 2025-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
EP4538292A2 (en) 2021-01-28 2025-04-16 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Also Published As

Publication number Publication date
US11396552B2 (en) 2022-07-26
KR20200141986A (ko) 2020-12-21
AU2019217207A1 (en) 2020-08-27
US20230059094A1 (en) 2023-02-23
AU2019217207B2 (en) 2025-12-18
JP2024024118A (ja) 2024-02-21
CA3090322A1 (en) 2019-08-15
US20210101991A1 (en) 2021-04-08
CN112119092A (zh) 2020-12-22
JP2021513367A (ja) 2021-05-27
EP3752532A1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
US20230059094A1 (en) Improved antagonistic anti-human cd40 monoclonal antibodies
CA3080120C (en) Anti-galectin-9 antibodies and uses thereof
AU2019202447B2 (en) Binding molecules specific for il-21 and uses thereof
KR101681818B1 (ko) T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
AU2016364891A1 (en) Anti-OX40 antibodies and methods of use thereof
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
US20250270328A1 (en) Klrb1 binding agents and methods of use thereof
JP2024509191A (ja) 抗ｖｉｓｔａ構築物およびその使用
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
RU2804456C1 (ru) Связывающие молекулы, специфичные к ил-21, и области их применения
AU2024322975A1 (en) Anti-ox40l antibody and use thereof
HK40126939A (zh) 抗vista构建体及其用途
HK40096227A (zh) 抗marco抗体和其用途
NZ725735B2 (en) Binding molecules specific for il-21 and uses thereof
HK1230976A1 (en) Binding molecules specific for il-21 and uses thereof
HK1230976B (en) Binding molecules specific for il-21 and uses thereof
NZ762893B2 (en) Binding molecules specific for il-21 and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19714877

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3090322

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020565253

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019217207

Country of ref document: AU

Date of ref document: 20190211

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20207025757

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019714877

Country of ref document: EP

Effective date: 20200914

WWR Wipo information: refused in national office

Ref document number: 1020207025757

Country of ref document: KR